ArticleCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
RSV vaccination in older adults: Addressing vaccine hesitancy using the 3C model.
Article in Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- New Tools Against Old Enemies: Respiratory Syncytial Virus (RSV) in Older Adults. A Narrative Review.Farmaceuticos comunitarios · 2026Article
- Navigating vaccine access, trust, coercion and regret: post-pandemic lessons on COVID-19 vaccination among newcomer communities in Alberta, Canada.BMC public health · 2026Article
- Limited discriminant validity of health belief and 3C models in high HPV vaccine coverage settings: the moderating role ofFrontiers in public health · 2026Article
- A process evaluation of Ontario, Canada's 2023-24 older-adult RSV vaccination program.Human vaccines & immunotherapeutics · 2025Article
- Awareness and vaccination willingness of middle-aged and elderly individuals in Southwest China toward to herpes zoster vaccine.Human vaccines & immunotherapeutics · 2025Article
- Article
- Prevention of respiratory syncytial virus disease across the lifespan in Italy.Pneumonia (Nathan Qld.) · 2025Review
- Parental Vaccine Hesitancy, Awareness, and Attitudes Toward Childhood Vaccination in Saudi Arabia.Patient preference and adherence · 2025Article
- Knowledge, attitude, and perception regarding the respiratory syncytial virus vaccine among healthcare professionals.Journal of pharmaceutical policy and practice · 2025Article
- From vaccine hesitancy to vaccine motivation: A motivational interviewing based approach to vaccine counselling.Human vaccines & immunotherapeutics · 2024Article
- Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.MedComm · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first vaccine against respiratory syncytial virus (RSV) targeting older adults was approved for use in Canada in August 2023. As a frequent first point of contact for Canadians seeking advice on vaccination and the most common setting for the administration of influenza vaccines, community pharmacies will also play a role in RSV vaccination efforts. To address vaccine hesitancy confidently and effectively, pharmacists must be equipped with knowledge of the factors that affect a person's decision on whether to be vaccinated or not. The 3C Model of Vaccine Hesitancy summarizes these as complacency, confidence and convenience. This article introduces the model and describes the often-underrecognized relevance of RSV to older adults, including risk factors and burden of disease. It also reviews the history and status of vaccine development and approval and presents clinical trial data to equip pharmacists to discuss RSV vaccination with older adults who express vaccine hesitancy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.